This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

ImmunoGen, Inc. Appoints Eric Guempel As Vice President Of Product Strategy And Program Management

ImmunoGen, Inc . (NASDAQ: IMGN), a biotechnology company that develops targeted anticancer therapies using its industry leading antibody-drug conjugate (ADC) technology, today announced the appointment of Eric Guempel as Vice President of Product Strategy and Program Management. Mr. Guempel brings to ImmunoGen more than 30 years of experience in the healthcare industry, including extensive experience in commercial functions related to the strategic development of novel oncology products. He reports to Dr. Charles Morris, Executive Vice President and Chief Development Officer of ImmunoGen.

“Eric joins ImmunoGen in a new position we established to enhance the strategic leadership of our proprietary programs, ensuring that as we advance our clinical compounds through proof of concept we implement development strategies for each compound that align with patient and market needs,” commented Dr. Morris.

Mr. Guempel has extensive experience leading cross-functional oncology product teams. He joins ImmunoGen from the Merck Serono division of Merck KGaA, where he was Head of New Therapies and Strategy for the Oncology Franchise. Prior to joining EMD Serono in 2008, Mr. Guempel held positions of increasing responsibility in the Oncology Strategic Business unit of Biogen Idec, including the position of Rituxan ® Team Leader. Prior to joining Idec in 2002, he held commercial positions supporting Neupogen ®, Neulasta ® and other oncology programs at Amgen. Prior to joining the marketing functions in 1998, Mr. Guempel held clinical research-related positions of increasing responsibility at Amgen, Berlex, and Ciba-Geigy (now Novartis). He holds an MS degree in Biology from Seton Hall University and an MBA from Pepperdine University.

About ImmunoGen, Inc.

ImmunoGen, Inc. develops targeted anticancer therapeutics. The Company’s ADC technology uses a tumor-targeting engineered antibody to deliver one of ImmunoGen's highly potent cancer-cell killing agents specifically to tumor cells; the Company has also developed antibodies with anticancer activity of their own. The most advanced compound with ImmunoGen’s ADC technology is Roche’s Kadcyla ®, which is marketed in the US by Genentech and is also gaining approvals internationally. Additional compounds are in clinical testing by ImmunoGen and through the Company’s partnerships with Amgen, Bayer HealthCare, Biotest and Sanofi. More information about ImmunoGen can be found at www.immunogen.com.

Kadcyla ®, Rituxan ®, Neupogen ® and Neulasta ® are registered trademarks of their respective owners.

Copyright Business Wire 2010

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs